3 ]Part 1 results of the SURVEYOR-II are presented at AASLD
A total of six abstracts were accepted for presentation at AASLD
, including presentations that contain off-study, follow-on data from a 14-day Phase 1b trial of telaprevir with pegylated interferon, and a 28-day Phase 1b trial of telaprevir with pegylated interferon and ribavirin.
The details for the AASLD
presentation are as follows:
Tibotec to present final safety and efficacy results from phase 2b PILLAR study of Once-daily TMC435 in late-breaker at AASLD
Additional telaprevir data being presented at AASLD
Additionally, there will be three poster presentations at the 2011 AASLD
Comparison and discussion of the data presented for the three most advanced HCV protease inhibitors at AASLD
Head of Liver Unit at the Erasmus MC University Hospital Rotterdam, The Netherlands and Lead Clinical Investigator of the study, who is presenting the data at AASLD
Commenting on the announcement by Medivir's development partner, Tibotec, Ron Long, Chief Executive of Medivir, said: "We are very pleased to have such exciting TMC435 data presented by our partner, Tibotec, at the AASLD
In the regularly revised HCV Practice Guidance of AASLD
and Infectious Diseases Society of America we recommend early treatment of chronic HCV infection before the development of severe liver disease and other complications to improve overall survival rates.
Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD
meeting in Boston, MA, on November 1, 2010.
Interim data from Tibotec's exploratory phase II study, VX950-C208, of telaprevir in treatment-naE[macron]ve patients with HCV genotype 1 were presented recently at AASLD